Form 4: Pfizer Executive Christoffel Boshoff Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Christoffel Boshoff, President of R&D at Pfizer, reports acquisition and disposal of common stock related to performance share awards.
Summary
- Christoffel Boshoff, President of R&D at Pfizer Inc., filed a Form 4 detailing changes in beneficial ownership of Pfizer's common stock.
- On February 27, 2025, Boshoff acquired 17,450 shares of common stock due to the earn-out of performance share awards.
- On the same day, 8,909 shares were disposed of to satisfy tax obligations related to the earn-out.
- Following these transactions, Boshoff directly owns 163,238 shares of Pfizer common stock and indirectly owns 664 shares through a Rule 16b-3 plan.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock transactions related to executive compensation. It doesn't inherently indicate positive or negative sentiment about the company's performance.
Industry Context
This filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their transactions in the company's stock. It reflects compensation and tax obligations related to performance-based equity awards.
Stakeholder Impact
- The filing provides transparency to shareholders regarding executive compensation and stock ownership.
Key Dates
| Date | Description |
|---|---|
| 02/27/2025 | Date of transaction: acquisition of 17,450 shares and disposal of 8,909 shares. |
| 03/03/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.